DDInter1956 DDInter837
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon alfa-2b
Peginterferon alfa-2b {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Zalcitabine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Golimumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tinidazole
Tinidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Candida albicans {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Zalcitabine {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dyspnoea {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Zalcitabine {u} (Compound) causes {v} (Side Effect) Respiratory tract congestion
Respiratory tract congestion {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Zalcitabine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may lead to a major life threatening interaction when taken with Golimumab
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Zalcitabine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Zalcitabine (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Zalcitabine (Compound) causes Respiratory tract congestion (Side Effect) and Respiratory tract congestion (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may lead to a major life threatening interaction when taken with Golimumab
Zalcitabine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab